FDA has approved Alunbrig or Brigatinib for first-line treatment of patients with ALK-positive metastatic non-small cell lung cancer, as detected by FDA-approved test. This approval has been based on phase III ALTA-1L trial….
Month: May 2020
U.S. FDA Gives Nod To Bristol-Myers Combo Therapy For Lung Cancer
Non-small cell lung cancer (NSCLC) accounts for about 85% of lung cancer cases. Lung cancer patients in advanced stages of the disease have received a new first-line treatment option. The U.S. Food…
FDA Approves Tabrecta, First Targeted Therapy for NSCLC
The FDA has approved Tabrecta, Novartis for the treatment of non-small cell lung cancer (NSCLC) that has spread to other parts of the body. NSCLC is the most common type of lung…
Lung Cancer Patients May Face Risk of Death from COVID-19
The continuous fear of COVID-19 is on the rise. With more and more people getting trapped in this pandemic, it also offers risk to those who already have health issues. The medical…